-
2
-
-
0027331190
-
Colonic toxicity of administered medications and chemicals
-
Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993; 88: 1684-1699
-
(1993)
Am J Gastroenterol
, vol.88
, pp. 1684-1699
-
-
Cappell, M.S.1
Simon, T.2
-
3
-
-
3142772194
-
Colonic toxicity of administered drugs and chemicals
-
Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004; 99: 1175-1190
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 1175-1190
-
-
Cappell, M.S.1
-
4
-
-
0038153907
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma
-
Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 8372-8377
-
-
Phan, G.Q.1
Yang, J.C.2
Sherry, R.M.3
Hwu, P.4
Topalian, S.L.5
Schwartzentruber, D.J.6
Restifo, N.P.7
Haworth, L.R.8
Seipp, C.A.9
Freezer, L.J.10
Morton, K.E.11
Mavroukakis, S.A.12
Duray, P.H.13
Steinberg, S.M.14
Allison, J.P.15
Davis, T.A.16
Rosenberg, S.A.17
-
5
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Jw, M.D.5
Garbe, C.6
Lebbe, C.7
Baurain, J.F.8
Testori, A.9
Grob, J.J.10
Davidson, N.11
Richards, J.12
Maio, M.13
Hauschild, A.14
Miller, W.H.15
Gascon, P.16
Lotem, M.17
Harmankaya, K.18
Ibrahim, R.19
Francis, S.20
Chen, T.T.21
Humphrey, R.22
Hoos, A.23
Wolchok, J.D.24
more..
-
6
-
-
0344341626
-
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
-
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712-4717
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 4712-4717
-
-
Hodi, F.S.1
Mihm, M.C.2
Soiffer, R.J.3
Haluska, F.G.4
Butler, M.5
Seiden, M.V.6
Davis, T.7
Henry-Spires, R.8
Macrae, S.9
Willman, A.10
Padera, R.11
Jaklitsch, M.T.12
Shankar, S.13
Chen, T.C.14
Korman, A.15
Allison, J.P.16
Dranoff, G.17
-
7
-
-
58349090027
-
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
-
Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-615
-
(2009)
Cancer Res
, vol.69
, pp. 609-615
-
-
Fong, L.1
Kwek, S.S.2
O'Brien, S.3
Kavanagh, B.4
McNeel, D.G.5
Weinberg, V.6
Lin, A.M.7
Rosenberg, J.8
Ryan, C.J.9
Rini, B.I.10
Small, E.J.11
-
8
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-830
-
(2007)
J Immunother
, vol.30
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
Royal, R.4
Sherry, R.M.5
Topalian, S.L.6
Suri, K.B.7
Levy, C.8
Allen, T.9
Mavroukakis, S.10
Lowy, I.11
White, D.E.12
Rosenberg, S.A.13
-
9
-
-
34548257760
-
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
-
Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872
-
(2007)
Oncologist
, vol.12
, pp. 864-872
-
-
Weber, J.1
-
10
-
-
78449244037
-
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
-
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507
-
(2010)
Semin Oncol
, vol.37
, pp. 499-507
-
-
di Giacomo, A.M.1
Biagioli, M.2
Maio, M.3
-
11
-
-
78449256966
-
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management
-
Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-498
-
(2010)
Semin Oncol
, vol.37
, pp. 485-498
-
-
Kaehler, K.C.1
Piel, S.2
Livingstone, E.3
Schilling, B.4
Hauschild, A.5
Schadendorf, D.6
-
12
-
-
33744792341
-
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
-
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289
-
(2006)
J Clin Oncol
, vol.24
, pp. 2283-2289
-
-
Beck, K.E.1
Blansfield, J.A.2
Tran, K.Q.3
Feldman, A.L.4
Hughes, M.S.5
Royal, R.E.6
Kammula, U.S.7
Topalian, S.L.8
Sherry, R.M.9
Kleiner, D.10
Quezado, M.11
Lowy, I.12
Yellin, M.13
Rosenberg, S.A.14
Yang, J.C.15
-
13
-
-
67349182592
-
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases
-
Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58: 1297-1306
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 1297-1306
-
-
di Giacomo, A.M.1
Danielli, R.2
Guidoboni, M.3
Calabrò, L.4
Carlucci, D.5
Miracco, C.6
Volterrani, L.7
Mazzei, M.A.8
Biagioli, M.9
Altomonte, M.10
Maio, M.11
-
14
-
-
67650848410
-
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis
-
Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009; 24: 321-325
-
(2009)
Cancer Biother Radiopharm
, vol.24
, pp. 321-325
-
-
Minor, D.R.1
Chin, K.2
Kashani-Sabet, M.3
-
15
-
-
70350244517
-
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab
-
Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 2538-2540
-
(2009)
Dig Dis Sci
, vol.54
, pp. 2538-2540
-
-
Johnston, R.L.1
Lutzky, J.2
Chodhry, A.3
Barkin, J.S.4
-
16
-
-
34347250137
-
Rituximab in patients with the steroid-resistant nephrotic syndrome
-
Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752
-
(2007)
N Engl J Med
, vol.356
, pp. 2751-2752
-
-
Bagga, A.1
Sinha, A.2
Moudgil, A.3
-
17
-
-
78650350834
-
Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: Multicentric report
-
Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5: 2207-2212
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 2207-2212
-
-
Gulati, A.1
Sinha, A.2
Jordan, S.C.3
Hari, P.4
Dinda, A.K.5
Sharma, S.6
Srivastava, R.N.7
Moudgil, A.8
Bagga, A.9
-
18
-
-
77950364195
-
Rituximab in refractory nephrotic syndrome
-
Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010; 25: 461-468
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 461-468
-
-
Prytuła, A.1
Iijima, K.2
Kamei, K.3
Geary, D.4
Gottlich, E.5
Majeed, A.6
Taylor, M.7
Marks, S.D.8
Tuchman, S.9
Camilla, R.10
Ognjanovic, M.11
Filler, G.12
Smith, G.13
Tullus, K.14
-
19
-
-
0035093233
-
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
-
Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211
-
(2001)
Rheumatology (Oxford)
, vol.40
, pp. 205-211
-
-
Edwards, J.C.1
Cambridge, G.2
-
20
-
-
2942537697
-
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
-
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581
-
(2004)
N Engl J Med
, vol.350
, pp. 2572-2581
-
-
Edwards, J.C.1
Szczepanski, L.2
Szechinski, J.3
Filipowicz-Sosnowska, A.4
Emery, P.5
Close, D.R.6
Stevens, R.M.7
Shaw, T.8
-
21
-
-
44449172514
-
Rituximab and nephrotic syndrome: A new therapeutic hope?
-
Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant 2008; 23: 11-17
-
(2008)
Nephrol Dial Transplant
, vol.23
, pp. 11-17
-
-
Ahmed, M.S.1
Wong, C.F.2
-
22
-
-
77954362764
-
Severe ulcerative colitis after rituximab therapy
-
Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010; 126: e243-e246
-
(2010)
Pediatrics
, vol.126
-
-
Ardelean, D.S.1
Gonska, T.2
Wires, S.3
Cutz, E.4
Griffiths, A.5
Harvey, E.6
Tse, S.M.7
Benseler, S.M.8
-
23
-
-
42549142171
-
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
-
El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008; 57: 714-715
-
(2008)
Gut
, vol.57
, pp. 714-715
-
-
El Fassi, D.1
Nielsen, C.H.2
Kjeldsen, J.3
Clemmensen, O.4
Hegedüs, L.5
-
24
-
-
36749004359
-
Exacerbation of ulcerative colitis after rituximab salvage therapy
-
Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13: 1365-1368
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 1365-1368
-
-
Goetz, M.1
Atreya, R.2
Ghalibafian, M.3
Galle, P.R.4
Neurath, M.F.5
-
25
-
-
34447121952
-
Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
-
Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2007; 2: 571-573
-
(2007)
J Thorac Oncol
, vol.2
, pp. 571-573
-
-
Gray, J.1
Murren, J.2
Sharma, A.3
Kelley, S.4
Detterbeck, F.5
Bepler, G.6
-
26
-
-
34247513403
-
Beva-cizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer
-
Adenis A, Vanseymortier L, Foissey D, Colombel JF. Beva-cizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. Gut 2007; 56: 734
-
(2007)
Gut
, vol.56
, pp. 734
-
-
Adenis, A.1
Vanseymortier, L.2
Foissey, D.3
Colombel, J.F.4
-
27
-
-
38649096270
-
"Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy
-
August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 2008; 97: 180-185
-
(2008)
J Surg Oncol
, vol.97
, pp. 180-185
-
-
August, D.A.1
Serrano, D.2
Poplin, E.3
-
28
-
-
42449136217
-
Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery
-
Abbrederis K, Kremer M, Schuhmacher C. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. Chirurg 2008; 79: 351-355
-
(2008)
Chirurg
, vol.79
, pp. 351-355
-
-
Abbrederis, K.1
Kremer, M.2
Schuhmacher, C.3
-
29
-
-
66949129437
-
Bowel perforation in non-small cell lung cancer after bevacizumab therapy
-
Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs 2009; 27: 184-187
-
(2009)
Invest New Drugs
, vol.27
, pp. 184-187
-
-
Schellhaas, E.1
Loddenkemper, C.2
Schmittel, A.3
Buhr, H.J.4
Pohlen, U.5
-
30
-
-
34248569455
-
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents
-
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639-647
-
(2007)
Arthritis Rheum
, vol.57
, pp. 639-647
-
-
Braun, J.1
Baraliakos, X.2
Listing, J.3
Davis, J.4
van der Heijde, D.5
Haibel, H.6
Rudwaleit, M.7
Sieper, J.8
-
31
-
-
36249008568
-
Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis
-
Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26: 2205-2206
-
(2007)
Clin Rheumatol
, vol.26
, pp. 2205-2206
-
-
Vandevyvere, K.1
Luyten, F.P.2
Verschueren, P.3
Lories, R.4
Segaert, S.5
Westhovens, R.6
-
32
-
-
67650891599
-
Psoriasiform and pustular eruption induced by etanercept and infliximab
-
Kuhara T, Watanabe D, Iwahori Y, Tamada Y, Yamamura M, Matsumoto Y. Psoriasiform and pustular eruption induced by etanercept and infliximab. Eur J Dermatol 2009; 19: 388-389
-
(2009)
Eur J Dermatol
, vol.19
, pp. 388-389
-
-
Kuhara, T.1
Watanabe, D.2
Iwahori, Y.3
Tamada, Y.4
Yamamura, M.5
Matsumoto, Y.6
-
33
-
-
34547543928
-
Tumor necrosis factor-alpha inhibitor associated ulcerative colitis
-
Prescott K, Costner M, Cohen S, Kazi S. Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am J Med Sci 2007; 333: 137-139
-
(2007)
Am J Med Sci
, vol.333
, pp. 137-139
-
-
Prescott, K.1
Costner, M.2
Cohen, S.3
Kazi, S.4
-
34
-
-
50649105058
-
Onset of ulcerative colitis under treatment with adalimumab
-
Tursi A, Penna A. Onset of ulcerative colitis under treatment with adalimumab. Am J Gastroenterol 2008; 103: 2410-2412
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 2410-2412
-
-
Tursi, A.1
Penna, A.2
-
35
-
-
0242411795
-
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
-
Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236
-
(2003)
Arthritis Rheum
, vol.48
, pp. 3230-3236
-
-
Davis, J.C.1
van der Heijde, D.2
Braun, J.3
Dougados, M.4
Cush, J.5
Clegg, D.O.6
Kivitz, A.7
Fleischmann, R.8
Inman, R.9
Tsuji, W.10
-
36
-
-
0037214122
-
Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis
-
Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74-76
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 74-76
-
-
Marzo-Ortega, H.1
McGonagle, D.2
O'Connor, P.3
Emery, P.4
-
37
-
-
13644269425
-
Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis
-
Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004; 39: 203-206
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.39
, pp. 203-206
-
-
Ruemmele, F.M.1
Prieur, A.M.2
Talbotec, C.3
Goulet, O.4
Schmitz, J.5
-
38
-
-
54949118761
-
Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept)
-
Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioǧlu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008; 10: 953-954
-
(2008)
Colorectal Dis
, vol.10
, pp. 953-954
-
-
Yazisiz, V.1
Avci, A.B.2
Erbasan, F.3
Yildirim, B.4
Terzioǧlu, E.5
-
39
-
-
40649108353
-
New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept
-
Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008; 35: 532-536
-
(2008)
J Rheumatol
, vol.35
, pp. 532-536
-
-
Song, I.H.1
Appel, H.2
Haibel, H.3
Loddenkemper, C.4
Braun, J.5
Sieper, J.6
Rudwaleit, M.7
-
40
-
-
70450222544
-
Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: Possible mechanisms of action
-
Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2009; 39: 176-181
-
(2009)
Semin Arthritis Rheum
, vol.39
, pp. 176-181
-
-
Haraoui, B.1
Krelenbaum, M.2
-
41
-
-
48049110733
-
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment
-
Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, Akkoc N. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 2912-2914
-
(2008)
World J Gastroenterol
, vol.14
, pp. 2912-2914
-
-
Sari, I.1
Birlik, M.2
Gonen, C.3
Akar, S.4
Gurel, D.5
Onen, F.6
Akkoc, N.7
-
42
-
-
84859601793
-
Colitis as a manifestation of infliximabassociated disseminated cryptococcosis
-
Osawa R, Singh N. Colitis as a manifestation of infliximabassociated disseminated cryptococcosis. Int J Infect Dis 2010; 14: e436-e440
-
(2010)
Int J Infect Dis
, vol.14
-
-
Osawa, R.1
Singh, N.2
-
43
-
-
67650088393
-
Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: A retrospective study
-
Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009; 48: 761-764
-
(2009)
Rheumatology (Oxford)
, vol.48
, pp. 761-764
-
-
Fouache, D.1
Goëb, V.2
Massy-Guillemant, N.3
Avenel, G.4
Bacquet-Deschryver, H.5
Kozyreff-Meurice, M.6
Ménard, J.F.7
Muraine, M.8
Savoye, G.9
le Loët, X.10
Tharasse, C.11
Vittecoq, O.12
|